Japan Lifeline
Financials
Estimates*
| JPY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 51.3b | 51.5b | 51.8b | 51.4b | 54.5b | 57.1b | 58.3b |
| % growth | (1 %) | - | 1 % | (1 %) | 6 % | 5 % | 2 % |
| EBITDA | 12.3b | 11.7b | 12.6b | 12.6b | 13.5b | 13.9b | 13.6b |
| % EBITDA margin | 24 % | 23 % | 24 % | 24 % | 25 % | 24 % | 23 % |
| Profit | 2.0b | 7.5b | 6.9b | 7.5b | 8.2b | 8.6b | 8.4b |
| % profit margin | 4 % | 15 % | 13 % | 15 % | 15 % | 15 % | 14 % |
| EV / revenue | 2.1x | 1.4x | 1.1x | 1.6x | 1.3x | 1.2x | 1.1x |
| EV / EBITDA | 8.9x | 6.3x | 4.7x | 6.6x | 5.2x | 4.8x | 4.6x |
| R&D budget | 1.7b | 2.2b | 2.3b | 2.4b | - | - | - |
| R&D % of revenue | 3 % | 4 % | 4 % | 5 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | N/A | IPO |
| Total Funding | - | ||
Recent News about Japan Lifeline
EditJapan Lifeline Co., Ltd. specializes in the development, manufacturing, and distribution of advanced medical devices, primarily focusing on cardiovascular treatments. Serving hospitals and medical institutions across Japan, the company operates in the highly specialized medical technology market. Japan Lifeline's business model involves both in-house product development and strategic partnerships with global medical device manufacturers. Revenue is generated through the direct sale of medical devices, including cardiac pacemakers, stent grafts, and ablation systems. The company emphasizes innovation and quality, aiming to improve therapeutic outcomes while minimizing patient discomfort.
Keywords: cardiovascular, medical devices, pacemakers, stent grafts, ablation systems, innovation, patient care, therapeutic outcomes, Japan, healthcare technology.
